AI news impact · China A-shares
Bide Pharmatech Co. Ltd. Class A (688073) news impact
On 2026-11-09 Wave Radar's AI rated the news on Bide Pharmatech Co. Ltd. Class A as neutral (impact score +5%).
Bide Pharmatech appeared only in automated ranking tables of STAR Market margin balance increments, without standalone disclosures.
- Direction
- Neutral
- Impact score
- +5%
- Confidence
- 40%
- Headlines read
- 5
- Date
- 2026-11-09
AI assessment
Regular listing in margin trading tracking tables without new corporate, financial, or strategic disclosures, indicating neutral impact.
Sector impact
Neutral impact with negligible influence on the pharmaceutical building blocks sector.
Headlines the AI read
- 【数据揭秘】融资客看好个股一览 AkShare/证券时报网 · 2026-11-09
- 314只科创板股融资余额环比增加 AkShare/证券时报网 · 2026-11-06
- 【数据揭秘】融资客看好个股一览 AkShare/证券时报网 · 2026-11-04
- 科创板股融资融券余额每日变动(11月3日) AkShare/证券时报网 · 2026-11-04
- 41只科创板股融资余额增加超500万元 AkShare/证券时报网 · 2026-11-04
Rating history
One rating per trading day the stock was covered.
More on Bide Pharmatech Co. Ltd. Class A
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.